dinoprostone + oxytocin

dinoprostone + oxytocin is a sequential pharmacological regimen used for the induction of labor, specifically evaluated in the POXY-PROM clinical trial conducted by the National Hospital of Obstetrics and Gynecology. The regimen involves the initial administration of a dinoprostone vaginal insert (Propess), a synthetic analogue of prostaglandin E2 (PGE2), to promote cervical ripening by softening and dilating the cervix through its action on prostaglandin E2 receptors. If active labor does not commence within a specified timeframe (e.g., 6 hours), it is followed by the intravenous administration of oxytocin, a peptide hormone that acts on oxytocin receptors in the uterine myometrium to stimulate rhythmic contractions. This sequential approach is designed to improve the success rate of vaginal delivery in pregnant women with term premature rupture of membranes (PROM) and an unfavorable cervix, potentially reducing the time to delivery and minimizing maternal and neonatal complications.

Brand names

Propess

Other names

Sequential induction with dinoprostone and oxytocin